Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17580522 | 0.87 | CCR5 (0.39) | QDPRCHEK1ALKTLR9TLR7 | |
| SCHEMBL521810 | 0.84 | QDPR (0.43) | QDPRCHEK1ALDH1A1CYP3A4TSHR | |
| SCHEMBL520062 | 0.84 | QDPR (0.48) | QDPRPDE4B | |
| SCHEMBL520554 | 0.84 | QDPR (0.68) | QDPRCHEK1ALDH1A1CYP3A4TSHR | |
| SCHEMBL29517150 | 0.84 | QDPR (0.68) | QDPRCHEK1ALDH1A1CYP3A4TSHR | |
| SCHEMBL20225757 | 0.83 | ALDH1A1 (0.53) | QDPRALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL520767 | 0.82 | NPM1 (0.49) | QDPRPDE4BALKTLR9TLR7 | |
| SCHEMBL310493 | 0.82 | QDPR (0.46) | QDPRALKTLR9TLR7TLR8 | |
| SCHEMBL520766 | 0.82 | NPM1 (0.49) | QDPRPDE4BALKTLR9TLR7 | |
| SCHEMBL17076795 | 0.80 | QDPR (0.55) | QDPRPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3372594-B1 | PYRIMIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER | HUMANWELL HEALTHCARE GROUP CO LTD (CN) | 2021-07-21 | — | — | EP | disclosed |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2021-04-20 | — | — | US | disclosed |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-10-15 | — | — | US | disclosed |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2020-08-11 | — | — | US | disclosed |
| US-10695347-B2 | Pyrimidine derivative and use thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-06-30 | — | — | US | disclosed |
| CN-106699743-B | Pyrimidine derivative and application thereof | 湖北生物医药产业技术研究院有限公司 | 2020-06-12 | — | — | CN | disclosed |
| US-20200078370-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2020-03-12 | — | — | US | disclosed |
| US-20190151330-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10220044-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20180338973-A1 | PYRIMIDINE DERIVATIVE AND USE THEREOF | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2018-11-29 | — | — | US | disclosed |
| EP-2188292-B1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-05-29 | — | — | EP | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-7981903-B2 | 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer | GLAXOSMITHKLINE LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | GLAXOSMITHKLINE LLC | 2010-08-12 | — | — | US | disclosed |
| EP-2188292-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009020990-A1 | 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D] PYRIMIDIN-4-YL) AMINO] BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER | SMITHKLINE BEECHAM CORPORATION (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338973-A1 | PYRIMIDINE DERIVATIVE AND USE THEREOF | ALK, DPYD, TYMP | QDPR 305/4885CHEK1 92/4885ALDH1A1 252/4885 |
| US-10695347-B2 | Pyrimidine derivative and use thereof | ALK, DPYD, TYMP | QDPR 305/4885CHEK1 92/4885ALDH1A1 252/4885 |
| US-20200078370-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | QDPR 30/4885CHEK1 757/4885ALDH1A1 142/4885 |
| US-20100204196-A1 | 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer | IGF1R, IGFBP2, IGFBP1 | QDPR 801/4885CHEK1 477/4885ALDH1A1 378/4885 |
| US-20200323874-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | QDPR 43/4885CHEK1 701/4885ALDH1A1 100/4885 |
| US-20190151330-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | QDPR 30/4885CHEK1 757/4885ALDH1A1 142/4885 |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | QDPR 40/4885CHEK1 1125/4885ALDH1A1 91/4885 |
| US-10980816-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | QDPR 46/4885CHEK1 1135/4885ALDH1A1 69/4885 |
| US-10220044-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | QDPR 40/4885CHEK1 1125/4885ALDH1A1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.